Human Intestinal Organoids and the Mouse S. Typhimurium Model Eva S. Rodansky1, Laura A. Johnson1, Benjamin Malamet1,2, Sha Huang1, Stephen G. Collins1, Lisa Hazelwood3, Jason R. Spence1, Peter D.R. Higgins1 1University of Michigan, 2Oakland University, 3Abbvie
intestinal fibrosis • A gene expression signature of fibrogenesis at diagnosis predicts future surgery in children with Crohn’s • Over time, fibrosis becomes independent of inflammation Preclinical inflammatory (minimal symptoms) Symptomatic inflammatory (not yet diagnosed) IBD diagnosis made (start treatment) Bowel Damage Accumulating Inflammation Improves Fibrosis Keeps Going Kugathasan, et al., Lancet. 2017;389:1710-1718 Johnson, Higgins, et al., Inflamm Bowel Dis. 2012; 18:460-71.
function to • Lay down extracellular matrix (in ulcers) – patch the hole • Actively contract to close edges of wounds (ulcers) • Intestinal myofibroblasts become resistant to apoptosis in a stiff extracellular matrix – just keep generating scar • Anti-inflammatory therapy can treat inflammation – but can’t stop this. • Often biologics arrive too late to prevent surgery.
proteins sensitize activated myofibroblasts to apoptosis and reduce pro-fibrotic gene expression • We hypothesized that ABT-263 would: • Reduce fibrogenic gene expression in intestinal myofibroblasts • Sensitize intestinal myofibroblasts to FasL-induced apoptosis • Reduce fibrogenic gene and protein expression in the human intestinal organoid (HIO) model of intestinal fibrosis. • Reduce fibrogenic gene and protein expression in the mouse Salmonella typhimurium model of intestinal fibrosis. Weder, B, Rogler, G, et al., IBD. 2018; 24: 1953-66.
myofibroblasts were co-treated with 100 ng/mL Fas ligand (FASL) and a range of doses of ABT-263 for 5 hours, followed by protein isolation and western blot analysis of cleaved PARP. FASL µM ABT-263 - + + + + - 0 0 0.1 0.3 1 1 PARP GAPDH
Dish” • Modeling the scarring and obstruction of Crohn’s disease Some intestinal organoids have a robust mesenchymal layer Treatment with TGF-b activates an expansion of mesenchyme and the ECM fibrogenic gene program: Collagen, fibronectin, a smooth muscle actin, and myosin light chain kinase are all activated Rodansky, Higgins, et al. 2015. Exp Mol Path 98:346-51. MICHIGAN IBD • IN VITRO MODELS OF FIBROSIS
• Human intestinal organoids (HIO) were co-treated with 2 ng/mL TGF-β and a low micromolar dose range of ABT-263 for 4 days • followed by isolation of RNA and qRT-PCR analysis • or by isolation of protein for western blot to analyze expression of fibrogenic genes and proteins.
Intestinal Organoid Gene Expression Gene expression: Data presented as random-effects meta-analysis of 4 distinct biologic replicates. Significant inhibition of expression of collagen and myosin light chain kinase is seen vs. TGFβ-mediated induction, with 10 uM ABT-263. ECM genes Fibronectin (FN1) Collagen 1(col1A1) Contractile genes Myosin light chain Kinase (MYLK) Alpha smooth muscle Actin (aSMA,acta2)
at 10 µM significantly (p < 0.05) reduced the expression of COL1A1 and MYLK genes. • No significant reduction seen for FN or ACTA2. • αSMA protein expression was significantly reduced with 10 uM (p=0.046) and 30 uM ABT-263 (p=0.0099).
normal microbiota w/ streptomycin Day 0: Inoculate with 3 x 106 S. typhimurium Grassl, et al., Gastroenterology 2008; 134:768; Johnson, et al. J Crohns Colitis. 2017 Jun 1;11(6):724-736. • Infectious colitis & fibrosis • Control inflammation (day 8 eradication of S. typh by levofloxacin) Day 21: Harvest tissue NL S. typh MICHIGAN IBD • RODENT FIBROSIS MODELS
model of intestinal fibrosis • Gross Pathology • Gross colon weight decreased by ABT-263 at high dose • Gene expression • TGF-β and CTGF gene expression decreased >50% (low and high dose) by ABT-263 • Col1A1 (25%) and IGF-1 (36%) also decreased to a lesser extent • Protein expression • αSMA protein expression decreased 51% (high dose) • Collagen 1 protein expression decreased 41% (high dose)
drug candidate in vitro, in 3D human organoid culture, and in a rodent model of intestinal fibrosis. • This compound appears to act in 2 ways: • Sensitizing activated myofibroblasts to apoptosis. • Reducing gene and protein expression of pro-fibrotic proteins • This compound has been shown to be safe in phase 1 trials in humans, now in phase 2 for solid tumors and ALL. • A prospective phase 2a study in stenotic CD is being planned.
higgi13425
revolveconf
lynnandtonic
bkeepers
swwweet
scottboms
iamctodd
kastner
michaelherold
palkan
jeffersonlam
akmur
dougneiner
